Genmab AS Total Liabilities
Genmab AS total liabilities. Based on the latest financial reports, Genmab AS (GMAB) has total liabilities worth $7.01 Billion USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Genmab AS (GMAB) defensive interval to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Genmab AS (2002–2025)
Total liabilities of Genmab AS from 2002 to 2025. This chart illustrates how Genmab AS's total liabilities have evolved over time, based on quarterly financial data. Check GMAB asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Genmab AS Competitors by Total Liabilities
The table below lists competitors of Genmab AS ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Clean Harbors Inc
NYSE:CLH
|
USA | $4.91 Billion |
|
Aluminum Corp of China Ltd
SHG:601600
|
China | CN¥100.94 Billion |
|
Beiersdorf Aktiengesellschaft
F:BEIA
|
Germany | €4.14 Billion |
|
Jones Lang LaSalle Incorporated
NYSE:JLL
|
USA | $9.86 Billion |
|
Toast Inc
NYSE:TOST
|
USA | $1.14 Billion |
|
Dawning Information Industry Co Ltd
SHG:603019
|
China | CN¥16.18 Billion |
|
Banco de Sabadell S.A
MC:SAB
|
Spain | €234.88 Billion |
|
SCB X Public Company Limited
BK:SCB
|
Thailand | ฿2.95 Trillion |
Liability Composition Analysis (2002–2025)
This chart breaks down Genmab AS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Genmab AS balance sheet assets.
Liquidity & Leverage Metrics
Genmab AS Total Liabilities Ratios Explained
Genmab AS total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.55 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Genmab AS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Genmab AS (2002–2025)
The table below shows the annual total liabilities of Genmab AS from 2002 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $7.01 Billion | -23.09% |
| 2024-12-31 | $9.11 Billion | +147.73% |
| 2023-12-31 | $3.68 Billion | +29.68% |
| 2022-12-31 | $2.84 Billion | +16.70% |
| 2021-12-31 | $2.43 Billion | +20.23% |
| 2020-12-31 | $2.02 Billion | +84.49% |
| 2019-12-31 | $1.10 Billion | +145.39% |
| 2018-12-31 | $446.64 Million | +35.04% |
| 2017-12-31 | $330.75 Million | -19.63% |
| 2016-12-31 | $411.54 Million | -1.03% |
| 2015-12-31 | $415.83 Million | -50.13% |
| 2014-12-31 | $833.74 Million | -22.23% |
| 2013-12-31 | $1.07 Billion | -18.15% |
| 2012-12-31 | $1.31 Billion | +21.49% |
| 2011-12-31 | $1.08 Billion | -23.08% |
| 2010-12-31 | $1.40 Billion | +51.63% |
| 2009-12-31 | $924.34 Million | -13.64% |
| 2008-12-31 | $1.07 Billion | -0.48% |
| 2007-12-31 | $1.08 Billion | +445.81% |
| 2006-12-31 | $197.05 Million | -21.70% |
| 2005-12-31 | $251.66 Million | +176.79% |
| 2004-12-31 | $90.92 Million | -2.94% |
| 2003-12-31 | $93.67 Million | -49.08% |
| 2002-12-31 | $183.97 Million | -- |
About Genmab AS
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervi… Read more